Cited by 3,777Medical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical ImagingLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 132 of the 157 references it cites were found in a registry or an index.

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Open access

Wahl, Richard L., Jacene, Heather, Kasamon, Yvette, Lodge, Martin A.·2009·Journal of Nuclear Medicine

DOI 10.2967/jnumed.108.057307PMC PMC2755245

Open this paper in CoChat — free account Open PDF

Abstract

UNLABELLED: The purpose of this article is to review the status and limitations of anatomic tumor response metrics including the World Health Organization (WHO) criteria, the Response Evaluation Criteria in Solid Tumors (RECIST), and RECIST 1.1. This article also reviews qualitative and quantitative approaches to metabolic tumor response assessment with (18)F-FDG PET and proposes a draft framework for PET Response Criteria in Solid Tumors (PERCIST), version 1.0. METHODS: PubMed searches, including searches for the terms RECIST, positron, WHO, FDG, cancer (including specific types), treatment response, region of interest, and derivative references, were performed. Abstracts and articles judged most relevant to the goals of this report were reviewed with emphasis on limitations and strengths of the anatomic and PET approaches to treatment response assessment. On the basis of these data and the authors' experience, draft criteria were formulated for PET tumor response to treatment. RESULTS: Approximately 3,000 potentially relevant references were screened. Anatomic imaging alone using standard WHO, RECIST, and RECIST 1.1 criteria is widely applied but still has limitations in response assessments. For example, despite effective treatment, changes in tumor size can be minimal in tumors such as lymphomas, sarcoma, hepatomas, mesothelioma, and gastrointestinal stromal tumor. CT tumor density, contrast enhancement, or MRI characteristics appear more informative than size but are not yet routinely applied. RECIST criteria may show progression of tumor more slowly than WHO criteria. RECIST 1.1 criteria (assessing a maximum of 5 tumor foci, vs. 10 in RECIST) result in a higher complete response rate than the original RECIST criteria, at least in lymph nodes. Variability appears greater in assessing progression than in assessing response. Qualitative and quantitative approaches to (18)F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments. Statistically significant changes in tumor standardized uptake value (SUV) occur in careful test-retest studies of high-SUV tumors, with a change of 20% in SUV of a region 1 cm or larger in diameter; however, medically relevant beneficial changes are often associated with a 30% or greater decline. The more extensive the therapy, the greater the decline in SUV with most effective treatments. Important components of the proposed PERCIST criteria include assessing normal reference tissue values in a 3-cm-diameter region of interest in the liver, using a consistent PET protocol, using a fixed small region of interest about 1 cm(3) in volume (1.2-cm diameter) in the most active region of metabolically active tumors to minimize statistical variability, assessing tumor size, treating SUV lean measurements in the 1 (up to 5 optional) most metabolically active tumor focus as a continuous variable, requiring a 30% decline in SUV for "response," and deferring to RECIST 1.1 in cases that do not have (18)F-FDG avidity or are technically unsuitable. Criteria to define progression of tumor-absent new lesions are uncertain but are proposed. CONCLUSION: Anatomic imaging alone using standard WHO, RECIST, and RECIST 1.1 criteria have limitations, particularly in assessing the activity of newer cancer therapies that stabilize disease, whereas (18)F-FDG PET appears particularly valuable in such cases. The proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting. Undoubtedly, subsequent revisions and enhancements will be required as validation studies are undertaken in varying diseases and treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.108.057307

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“If tumors other than these 5 progress unequivocally, progression has occurred (39,40).”
Background
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in advanced hepatocellular carcinoma.
Spinzi, G., & Paggi, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc081780 · Cited by 7,303 · cited 2×
“Similar findings of prolonged life, with limited antitumor size response by RECIST, have been seen in hepatomas treated by sorafenib (44,45).”
Background
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537 · cited 5×
“Progression in the lungs, particularly in the presence of potential inflammation or infection while a patient is on treatment, should be viewed with great caution, as discussed in the revised response criteria in lymphoma (32,33).”
BackgroundMethodInfluential
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
EXPRESSION OF UBIQUITIN-SPECIFIC PROTEASE 14 IN HUMAN PANCREATIC CANCER CELL LINES AND CANCER TISSUES
Ishiwata, T., Cho, K., Ishiwata, S., Fujii, T., Kawahara, K., Kudo, M., Uchida, E., Tajiri, T., & Naito, Z. (2005) · doi:10.1097/01.mpa.0000193687.52588.d4 · Cited by 2,420
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi, H., Charnsangavej, C., Faria, S., Macapinlac, H., Burgess, M., Patel, S. R., Chen, L. L., Podoloff, D., & Benjamin, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,508 · cited 7×
“Additional anatomic characteristics of GIST, such as the development of mural nodules, but not necessarily with tumor growth because of the predominantly cystic nature of the tumors, are indicative of progression and of a poor outcome (48,49).”
BackgroundInfluential
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
Juweid, M., Stroobants, S., Hoekstra, O., Mottaghy, F., Dietlein, M., Guermazi, A., Wiseman, G., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,377 · cited 4×
“Progression in the lungs, particularly in the presence of potential inflammation or infection while a patient is on treatment, should be viewed with great caution, as discussed in the revised response criteria in lymphoma (32,33).”
BackgroundInfluential

Show all 157 references

Research works printed but not linked: 23

1981, Cancer Clin Trials., 4, 451
1988, J Nucl Med., 29, 421
2006, J Nucl Med., 47, 901
2007, J Nucl Med., 48, 19S
2006, J Nucl Med., 47, 1059
10.1002/cncr.24060 · DOI
2007, J Nucl Med., 48, 36S
2005, J Nucl Med., 46, 983
2006, J Nucl Med., 47, 14
1990, J Nucl Med., 31, 369
2004, J Nucl Med., 45, 1519
10.1158/0008-5472.CAN-06-2030 · DOI
2004, J Am Coll Surg., 199, 1
1999, J Nucl Med., 40, 1771
1995, J Nucl Med., 36, 252
2004, J Nucl Med., 45, 784
1994, J Nucl Med., 35, 1308
10.1200/JCO.2006.06.8999 · DOI
2006, J Nucl Med., 47, 603
1993, J Nucl Med., 34, 773
2004, J Nucl Med., 45, 17
2001, J Nucl Med., 42, 1605
2001, J Nucl Med., 42, 1596

Sorted by citations

Items 701–800 of 1,041

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
Tian, A.-J., Lv, H.-Y., Liu, W., Zhao, J.-B., Zhao, S., Wang, K., & Song, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1099164 · Cited by 2
“Internationally, there are four main criteria for the efficacy evaluation in bone metastases: those of the International Union Against Cancer (UICC) (9), the World Health Organization (WHO) (10), the MD Anderson Cancer Center USA (MDA) (2), and the Positron Emission Tomography Response Criteria in Solid Tumor (PERCIST…”
Background
Precision of quantitative parameters of 18F-FDG PET/CT in a rabbit VX2 tumor model
Guo, B., Hu, L., Cai, Q., Cheng, Y., Shang, J., Tang, Y.-J., Ling, X.-Y., Gong, J., Liang, S. H., Wang, L., et al. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-1079 · Cited by 2
“0, defined 30% as a cut-off value on the basis of previous studies on repeatability; when the SULpeak before and after treatment changes in more than 30%, it is associated with a metabolic response or disease (4).”
BackgroundMethodInfluential
Evaluation of data-driven respiratory gating for subcentimeter lesions using digital PET/CT system and three-axis motion phantom
Fukai, S., Daisaki, H., Shimada, N., Ishiyama, M., Umeda, T., Yamashita, K., Miyaji, N., Takiguchi, T., Kawakami, H., & Terauchi, T. (2022) · Biomedical engineering and physics express · doi:10.1088/2057-1976/aca90d · Cited by 2
Editorial. Assessing treatment response following stereotactic body radiotherapy for spinal metastases.
Roth, S. G., & Chambless, L. (2022) · Neurosurgical Focus · doi:10.3171/2022.8.focus22438 · Cited by 2
A Retrospective Study of Chemotherapy and 3D-Image-Guided Afterloading Intracavitary Radiotherapy in Locally Advanced Cervical Cancer
Li, X.-J., An, C., Feng, C., Sun, J.-R., Lu, H., Yang, X.-D., Wang, K., & Wang, R. (2022) · Journal of Oncology · doi:10.1155/2022/9578436 · Cited by 2
18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002
Subramaniam, R., Demora, L., Yao, M., Yom, S., Gillison, M., Caudell, J., Waldron, J., Xia, P., Chung, C., Truong, M., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264424 · Cited by 2
“The advantage of standardized qualitative interpretation criteria is the ease and rapid deployment in a clinical practice setting (15) while maintaining similar accuracy of semiquantitative interpretation methods such as PERCIST (16) and other methods (11), which require more stringent standard methods of performing t…”
Method
Editorial on Special Issue “Quantitative PET and SPECT”
van Velden, F. V., & de Geus-Oei, L. D. (2022) · Diagnostics · doi:10.3390/diagnostics12081989 · Cited by 2
“In this Special Issue, Roef and colleagues determined the repeatability of 68Ga-PSMA lesion uptake in both relapsing and metastatic tumors and showed that a minimum response of 50% seems appropriate in this clinical situation [10], which is higher than 30% recommended by the PET Response Criteria in Solid Tumors [11].”
Background
Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET—A Significant Improvement Over Prediction Equations
Riauka, T., Baracos, V., Reif, R., Juengling, F., Robinson, D. M., Wieler, M., & McEwan, A. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.812777 · Cited by 2
[Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response].
Storme, S., Debieuvre, D., Souquet, P., Toffart, A., & Couraud, S. (2022) · Revue des maladies respiratoires · doi:10.1016/j.rmr.2022.06.006 · Cited by 2
Evaluation of physiological Waldeyer’s ring, mediastinal blood pool, thymic, bone marrow, splenic and hepatic activity with 18F-FDG PET/CT: exploration of normal range among pediatric patients
April, G., Bruycker, J. D., Decaluwe, H., Haddad, É., Lambert, R., & Turpin, S. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01748-2 · Cited by 2
“In children, it is noteworthy that, due to large variations in size between age groups, it is difficult to use the same type of ROI in each patient and each organ as suggested by some authors [4, 11].”
Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method
Rijo-Cedeño, J., Mucientes, J., Villarreal, I., Royuela, A., Vicente, P. G., & García-Berrocal, J. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-022-07401-y · Cited by 2
“To reduce this variability, some authors suggest to either use a background-level threshold [24, 28, 30, 31] or a gradient-based method [18, 20, 21].”
Method
2-Deoxy-2-[18F] Fluoro-d-Glucose PET/Computed Tomography: Therapy Response Assessment in Head and Neck Cancer.
Sheikhbahaei, S., Subramaniam, R., & Solnes, L. (2022) · PET Clinics · doi:10.1016/j.cpet.2021.12.003 · Cited by 2
Investigation of EGFR mutations in non‑small cell lung cancer usually undetectable by PCR methods
Matsubara, T., Nakajima, E., Namikawa, H., Ono, S., Takada, I., Ohira, T., Morishita, Y., Miyazaki, T., Furukawa, K., & Ikeda, N. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2447 · Cited by 3
“The cases with complete metabolic response were confirmed using the 100% standardized uptake value (SUV) normalized to lean body mass (LBM) decline, according to PERCIST.”
MethodInfluential
18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
Nakamura, M., Satake, H., Sagawa, T., Takagane, A., Sekikawa, T., Oguchi, K., Kaji, T., Takeuchi, M., Ichikawa, W., & Fujii, M. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00173-1 · Cited by 2
“The response criteria assessed using FDG-PET in this study were defined based on EORTC (European Organisation for Research and Treatment of Cancer) and PERCIST (Positron Emission Tomography Response Criteria in Solid Tumors) criteria [11, 12].”
Method
Relationship between total lesion glycolysis of primary lesions based on 18F-FDG PET/CT and lymph node metastasis in gastric adenocarcinoma: a cross-sectional preliminary study
Xue, X.-Q., Wang, B., Yu, W.-J., Zhang, F.-F., Niu, R., Shao, X., Shi, Y., Yang, Y.-S., Wang, J.-F., Li, X.-F., et al. (2021) · Nuclear medicine communications · doi:10.1097/mnm.0000000000001475 · Cited by 2
Curative-Intent Cryoablation for Bone Metastases: Study Protocol for BOREALIS, a Prospective Multicentre Observational Investigation
Cazzato, R., Buy, X., Gómez, F. M., Deschamps, F., Arnold, D., Filippiadis, D., Jennings, J., Schaefer, N., Schneegans, O., Tsoumakidou, G., et al. (2026) · Cardiovascular and Interventional Radiology · doi:10.1007/s00270-026-04550-z · Cited by 1
Metabolic Response to an Individualized Multimodal Treatment Strategy in Advanced Pancreatic Adenocarcinoma: A Case Report
İyikesici, M. S., Oncul, O., Hallaç, M., Şen, S., Taflan, Ş., Öncül, S., Duraj, T., & Seyfried, T. N. (2026) · Current Oncology · doi:10.3390/curroncol33080489 · Cited by 1
“An early (approximately four-week) metabolic response has been shown to serve as an interim imaging biomarker for overall survival in pancreatic adenocarcinoma, while high FDG uptake (high SUVmax) is associated with worse survival [13].”
Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China
Lei, C., Cai, Y., Tang, Y.-P., Chen, S.-H., Ji, H.-S., Zhu, J.-C., Gao, H., Zapała, Ł., Li, X., Cai, H.-Z., et al. (2026) · The Lancet Medical Imaging & Theranostics · doi:10.1016/j.lanmit.2026.100005 · Cited by 1
Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom
Amerikanou, R., Munir, T., Bowles, K., McNamara, C., Chavda, N., Price, E., Adiyodi, J., Coles, A., Kelsey, P., Smith, J., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70617 · Cited by 1
Global Curriculum in Surgical Oncology: 2nd Edition, 2026
Are, C., Stättner, S., Leiphrakpam, P. D., Pitzl, T., Audisio, R. A., Rubio, I. T., & Berman, R. S. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19543-y · Cited by 1
“35 An understanding of alternatives to RECIST, such as PERCIST, 36 WHO criteria, 37 Choi criteria 38 and morphologic criteria 39 (to assess response following immunotherapy that cannot be accurately assessed with RECIST) is essential.”
Vitamin D3 Supplementation Modulates C-MYC/VEGF and Improves Chemotherapy Outcomes in Metastatic CRC Patients: Integrated Clinical-Mechanistic Evidence.
Rahman, A., Hassan, N., Hamza, M. S., Gaber, N., Omran, M., Shouman, S. A., & Khallaf, S. M. (2026) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2026.27.6.2279 · Cited by 1
“Imaging studies were conducted at baseline and after 60 days determining tumor response using RECIST version 1.1 criteria [9].”
Influential
Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [1⁸F]FDG PET/CT metrics in metastatic melanoma
Sachpekidis, C., Vagenas, T. P., Müller, M., Strauss, D. S., Kopp‐Schneider, A., Pan, L., Hassel, J. C., Matsopoulos, G. K., & Dimitrakopoulou‐Strauss, A. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07915-1 · Cited by 2
“…for Research and Treatment of Cancer (EORTC) 1999 criteria [32] ● Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) [33] ● PET Response Evaluation Criteria for IMmunoTherapy (PERCIMT) [34] ● Immunotherapy-modified PERCIST (imPERCIST5) [35] ● Immune PERCIST…”
Safety and Efficacy of HexaBody‐DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Overdijk, M., Strumane, K., Plummer, R., LoRusso, P. M., Ahnert, J. R., Banerji, U., Garralda, E., Calvo, E., Si, H., Hoevenaars, N., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70546 · Cited by 1
“To explore whether HexaBody-DR5/DR5 exhibited biological activity, we analyzed a subset of patients by assessing metabolic changes in their tumors using PERCIST criteria [18].”
Efficacy of intra-arterial [177Lu]Lu-DOTATATE vs. continuation intravenous [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumors.
Bagasariya, R., Parghane, R., Shetty, N., Gala, K., Kulkarni, S., & Basu, S. (2026) · Nuclear medicine communications · doi:10.1097/mnm.0000000000002173 · Cited by 1
Global curriculum in surgical oncology: 2nd edition, 2026.
Are, C., Stättner, S., Leiphrakpam, P. D., Pitzl, T., Audisio, R. A., Rubio, I. T., & Berman, R. S. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111753 · Cited by 1
Generalizable CT-free PET attenuation and scatter correction via few-shot cross domain adaptation
Wang, H., Wen, M., Qiao, X., Chen, Q., An, Y., Chen, X., Guo, R., Huang, Q., Zhu, X., Cheng, Z., et al. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02760-w · Cited by 1
“The PERCIST 1.0 criteria 40 suggests that the aorta can serve as a reference for lesion measurement when liver is abnormal, with primary tumor uptake expected to exceed 2 × the SUL (SUV normalized by lean body mass) mean of blood pool.”
Influential
Superiority of [68Ga]Ga-FAPI-04 Over [18F]-FDG PET/CT and Conventional Imaging in Detecting Peritoneal Carcinomatosis
Chen, X.-L., Wang, M.-J., Zhao, Y., Pang, X., Yang, R.-X., Jing, F.-L., Liu, Y.-N., Dai, M., Sun, Y.-H., Fu, Q., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19787-8 · Cited by 1
Survival of patients with complete metabolic response on [18F]FDG PET/CT after chemotherapy prior to transplantation for colorectal liver metastases
Stern, N. M., Dueland, S., Line, P., Syversveen, T., & Grut, H. (2026) · Scandinavian Journal of Surgery · doi:10.1177/14574969261438696 · Cited by 1
Standardising definitions, endpoints, and reporting parameters for clinical studies of stereotactic body radiation therapy in bone metastases: An international Delphi consensus.
Lee, S.-F., Wong, H. C. Y., Oldenburger, E., Raman, S., Marta, G., Chan, A. W., Rades, D., van der Linden, Y. M., der Velden, J. M. V., Nguyen, Q.-N., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116783 · Cited by 1
Enhanced Lymphoma Subtype Classification and Prognosis Using Machine Learning with 18F-FDG PET/CT Radiomics: Beyond SUVmax
Hasanabadi, S., Aghamiri, S. R., Abin, A. A., Vosoughi, H., Emami, F., Karam, M. B., Nejabat, M., Dorudinia, A., Arabi, H., & Zaidi, H. (2026) · Nuclear medicine and molecular imaging · doi:10.1007/s13139-026-01017-4 · Cited by 1
“Following the delineation of the lesions, a 3-dimensional region of interest (ROI) was defined on the right lobe of the liver, where no lesions were present, in accordance with the PERCIST criteria [ 34 ], for calculating TLR radiomics.”
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) – a randomized, open-label, multicenter phase II trial protocol
Shafie, R. A. E., Willmann, J., Gkika, E., Schimek‐Jasch, T., Miederer, M., Bozorgmehr, F., Griesinger, F., Manapov, F., Christopoulos, P., Hehr, T., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15901-x · Cited by 2
“1 criteria during tumor evaluation at the end of CRT [40, 41].”
Case Report: Complete metabolic responses to trastuzumab–deruxtecan in HER2-altered solid tumors: two illustrative cases
le Meur, C., Roux, P. L., Alemany, P., Chauvelot, F., Pradier, O., Niel, C., Bellange, A., Chouaid, C., Massard, C., & Amrane, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1752694 · Cited by 1
“Metabolic response assessment using PET-based criteria, such as the PET Response Criteria in Solid Tumors (PERCIST), may provide complementary information to conventional anatomical criteria like RECIST, allowing earlier and more sensitive evaluation of treatment ef ﬁ cacy (17, 18).”
PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol
Geier, M., Amrane, K., Bourhis, D., Roux, P. L., Nguyen, J., Dhamelincourt, E., Descourt, R., Quéré, G., Guégan, M., Besse, B., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345990 · Cited by 1
“0) [24] (and iPERCIST [25] when applicable).”
Inflammatory and Nutritional Biomarkers Predict Response to Neoadjuvant Dual Anti-HER2 Therapy in HER2-Positive Breast Cancer: A Retrospective Cohort Study
Şahinli, H., Uyar, G., & Yeşilbaş, E. (2026) · Cancer Management and Research · doi:10.2147/cmar.s598948 · Cited by 1
“12,13 Target lesions were defined based on the highest standardized uptake value normalized to lean body mass (SULpeak) of the most metabolically active lesion.”
Fluorine-18 fluorodeoxyglucose PET/computed tomography-based scoring systems in oncology: pictorial review from clinical practice.
Patro, S. S., Bishnoi, K., Agrawal, K., Gnanasegaran, G., Parida, G., & Subudhi, K. (2026) · Nuclear medicine communications · doi:10.1097/mnm.0000000000002142 · Cited by 1
Assessing Respiratory Motion Stability of Novel 18F-Fluorodeoxyglucose Positron Emission Tomography-Derived Morphological Features
Tan, S. I., Lue, K., Chen, Y.-H., Chu, S.-C., Lin, C.-B., & Liu, S.-H. (2026) · Diagnostics · doi:10.3390/diagnostics16070994 · Cited by 1
“Both metrics were derived using two distinct intensity definitions, maximum intensity voxel (SUVmax) and peak intensity voxel (SUVpeak) [19], yielding four features: NHOCmax, NHOCpeak, NHOPmax, and NHOPpeak.”
Improving Breast Cancer Diagnosis from Imaging Measurements Using Disc T-Spherical Fuzzy Sets: A Quantitative Approach to Uncertainty
Ameen, Z., Salih, H. F. M., Alharbi, B., & Asaad, B. A. (2026) · Results in Engineering · doi:10.1016/j.rineng.2026.110252 · Cited by 1
Impact of local tumor-to-background uptake ratio on PET metabolic response assessment
Mehrara, E., Mohamed, M., van Essen, M., & Urdaneta, J. L. (2026) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncaf145 · Cited by 1
“It relies on quantitative SUV measurements to assess treatment response over time [9].”
18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors
Amrane, K., le Meur, C., Bourhis, D., Berthou, C., Pradier, O., Misery, L., Legoupil, D., Etienne, M., Fontaine, G., Leleu, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1642620 · Cited by 1
“The MEL-RAD model was built for the prediction of the 1y-PFS assessed with FDG-PET/CT according to PERCIST criteria (25).”
Positronen-Emissions-Tomographie bei Sarkomen
Fendler, W., Kessler, L., Himmen, S., & Hamacher, R. (2026) · Die Radiologie · doi:10.1007/s00117-026-01573-y · Cited by 1
Role of 18F-FDG PET/CT Metabolic Parameters in Treatment Response Evaluation and Prognostic Assessment of Hodgkin Lymphoma: A Retrospective Analysis
Uysal, H., Gültekin, A., Güler, N., Türk, N., Şimşek, F., Şengöz, T., & Yüksel, D. (2026) · Turkish journal of haematology : official journal of Turkish Society of Haematology · doi:10.4274/tjh.galenos.2026.76768 · Cited by 1
“In our study, the use of the 40% SUVmax threshold, which has been validated in phantom studies, provided a methodologically sound basis [28].”
Feasibility Study of 18F-FDG PET Short-Duration Scan in Underweight Patients with Lung Cancer
Sagara, H., Akamatsu, G., Mano, C., Inaki, A., & Inoue, K. (2026) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.271073 · Cited by 1
Prognostic significance of hypermetabolic contralateral cervical lymph node in patients with oral and oropharyngeal squamous cell carcinoma.
Hennocq, Q., Truchard, E., Chargari, C., Maisonobe, J., Maingon, P., Kas, A., Bouaoud, J., Bertolus, C., & Foy, J.-P. (2026) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2026.102740 · Cited by 1
Harmonisation of standard uptake values in long-axial field-of-view PET/CT: an exploratory study
Li, Y., Zhang, Z.-Y., Bai, H., Lu, X., & Pang, H. (2026) · EJNMMI Physics · doi:10.1186/s40658-025-00819-3 · Cited by 1
“SUV harmonisation has demonstrated clinical significance in multi-centre SUV comparison for both drug clinical trials and longitudinal patient follow-up [23–26].”
Integrated primary tumor and all metastatic lymph nodes radiomics from 18 F-FDG PET/CT for precise M1 subclassification in nasopharyngeal carcinoma
Zhang, Y., Xu, S.-S., & Hu, Y.-X. (2026) · BMC Cancer · doi:10.1186/s12885-026-15589-z · Cited by 1
“Normalized Parameters: GNmax/GNmean (glucose-normalized SUVmax/SUVmean) [30, 32]; SULmax (lean body mass-normalized SUVmax) [33]; SUSmax (body surface area-normalized SUVmax) [34].”
Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer
Fabi, A., Giordani, E., Ricciardi, E., Arpino, G., Allegretti, M., Ferretti, G., Omarini, C., Zambelli, A., Mandoj, C., Botticelli, A., et al. (2026) · Journal of experimental & clinical cancer research : CR · doi:10.1186/s13046-025-03605-2 · Cited by 1
“However, the limitations of a purely anatomical assessment of response to treatment are widely recognized, and additional RECIST criteria have been proposed to evaluate Positron Emission Tomography (PET) and immune Response (PERCIST and iRECIST/imRECIST) [2, 3].”
The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving 177Lutetium-PSMA-therapy
Ranjan, A., Padden-Modi, M., Abdel-Aty, H., Galante, J. R., Wan, S., Maricar, A., Adesina, A. A., Drake, B., Yusuf, S., Cook, G., et al. (2026) · Insights into Imaging · doi:10.1186/s13244-025-02151-x · Cited by 1
“0) assesses metabolic response using SUV changes in the most metabolically active lesion ( ‘ hottest lesion ’ ) to evaluate early molecular response before anatomical changes [52].”
Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial
Berthod, G., Cisarovsky, C., Petrova, T. V., Decosterd, L., Choong, E., Celestini, D., Cuendet, M., Boughdad, S., Prior, J. O., Meuwly, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03279-9 · Cited by 1
“…University of Lausanne, using commercially available kit from Sigma Aldrich Human angiopoietin (RAB0015-1KT), Merck Millipore Thrombospondin1 Human Sepsis Immune Response (HSP3MAG-63K), Human Angiogenesis Panel 2, sVEGFR1, sVEGFR2, Angiostatin, Thrombospondin-2 (HANG2MAG-12K-04), Biorad - Bioplex…”
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
Kubeczko, M., d’Amico, A., Chrabański, O., Handkiewicz-Junak, D., Polakiewicz-Gilowska, A., Swiderska, K., Mianowska-Malec, M., Leśniak, A., Lanoszka, B., Lisovska, N., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02191-7 · Cited by 2
“Importantly, PHERGain did not derive an optimal base-line SUVmax cut-off; instead, it used SUVmax—as in our study—rather than SULpeak, the parameter required by PERCIST criteria [45].”
Response evaluations in non-small cell lung cancer patients undergoing immunotherapy: a comparative analysis of RECIST 1.1, iRECIST, and imRECIST criteria
Shih, Y.-J., Chen, J.-H., Yeh, L.-R., Lin, C.-Y., Huang, S., & Yang, C.-Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-03115-3 · Cited by 1
“Notably, response assessment based on metabolic criteria such as Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) [ 14 ] was not conducted.”
Total-Body PET/CT Metabolic Response in Esophageal Squamous Cell Carcinoma.
Yang, R., Lu, X., Tang, W., Nardo, L., Xie, Y., Al-ibraheem, A., Zhang, L., Zhao, W., Rominger, A., Tan, L.-J., et al. (2025) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2025.11.010 · Cited by 1
Emerging Advances in Nanomedicine for Targeted Cancer Photoimmunotherapy and Photo‐Immunometabolic Therapy
Chota, A., Sarbadhikary, P., Abrahamse, H., & George, B. P. A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70042 · Cited by 1
“Anatomical (RECIST/iRECIST), metabolic (FDG-PET), and immunological readouts (change in CD8 + TILs, ctDNA kinetics, cytokine profiling) should be combined for response evaluation in order to capture both systemic immune activation and local control (Ryssel et al. 2025; Wahl et al. 2009).”
Minimal clinically important difference of EQ-5D-5L, SF-6Dv2, and QLU-C10D in hematologic malignancy patients in China
Li, F.-Y., Li, J., Zhang, A.-X., Wu, J., Luo, N., Liu, P., & Wang, P. (2025) · Health and Quality of Life Outcomes · doi:10.1186/s12955-025-02383-x · Cited by 1
“Tumor relapse was assessed according to the treat-ment regimen [51–53].”
Influential
Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis
Ishida, Y., Watanabe, S., Sakakibara-Konishi, J., Ikezawa, Y., Kikuchi, H., Kawai, Y., Kimura, H., Nakakubo, S., Hirata, K., Kudo, K., et al. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01869-4 · Cited by 1
“The value of a 1 cm 3 -volume spherical volume of interest (VOI) where FDG uptake centering around the hottest point in the foci was defined as the SUVpeak [17].”
Centroid to SUVpeak distance is a prognostic PET biomarker in high-grade gliomaPreprint
Bosque, J. J., Molina-García, D., Pérez-Beteta, J., Vicente, A. G., & Pérez-García, V. M. (2025) · medRxiv · doi:10.1101/2025.08.22.25334230 · Cited by 1
“The maximum metabolic activity in the filtered image is known as SUVpeak and indicates the region of maximum uptake in the filtered image, being thus less affected by noise than the SUVmax ( 22 ).”
Novel Gradient-based Approach to Spatially Fractionated Radiotherapy: Implementation and Preliminary Clinical Results
Ortega, M. S., Barrera, D. G., Llorente, D. G., Villalba, S. R., Molina, F. B., Martín, J. D. L., & Perez-Calatayud, J. (2025) · Cureus · doi:10.7759/cureus.91740 · Cited by 1
“0 [15].”
Comparative evaluation of Ordered Subset Expectation Maximization and Bayesian Penalized Likelihood algorithms for PET/CT image reconstruction in various malignancies using 18F-FDG and 68Ga-PSMA-11 tracers
Naeimi, A., Harsini, S., Aghdam, R. A., Klein, R., & Abbaspour, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1597919 · Cited by 1
“%) and that BPL-derived increments, while statistically signi ﬁ cant, are improbable to affect clinical interpretation or PET Response Criteria in Solid Tumors (PERCIST), given reconstruction techniques stay consistent for longitudinal studies (27, 30).”
[18F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis
Bayerl, C., Kaufmann, J., Metzger, G., Rogasch, J., Amthauer, H., Schatka, I., Brenner, W., van der Giet, M., & Furth, C. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07479-6 · Cited by 1
“Metabolic progression between FU1 and FU2 was defined as an increase of at least 30% of the peak standardized uptake value corrected for lean body mass (SUL peak ), adapted from PERCIST 1.0 criteria [ 23 , 24], ensuring a standardized eval - uation of PET-derived metabolic activity.”
Influential
Use of relative Patlak plot Ki′ images as an alternative to standard Patlak plot Ki images in clinical practice
Nakajo, M., Kawakami, H., Kiyao, Y., Hirahara, M., Katsuki, A., Tani, A., Eizuru, Y., Takumi, K., Kamimura, K., Kanzaki, F., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01295-7 · Cited by 1
“Despite its widespread utility as a biomarker in oncology [22], SUV has notable limitations [23–29].”
Immunotherapy and Targeted Therapy Considerations in Head and Neck Oncology.
Dagher, R., Khalaf, A. M., Ferrarotto, R., & Learned, K. (2025) · The Radiologic clinics of North America · doi:10.1016/j.rcl.2025.07.002 · Cited by 1
Novel molecular imaging approaches in oncology: towards a more accurate estimation of tumour response
Sharkey, A. R., Pervez, A., & Cook, G. J. R. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001166 · Cited by 1
Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors
Saadani, H., Aalbersberg, E. A., Kayembe, M. T., Haanen, J. B. A. G., Hoekstra, O. S., Boellaard, R., & Stokkel, M. P. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-95713-4 · Cited by 1
Dynamic profiles of early biological responses to predict the treatment efficacy of proton therapy in liver cancer assessed with in vivo kinetic [18F]-FDG PET/MRI
Chung, Y.-H., Cho, I.-C., Jhang, F., Weng, C.-C., Lin, G., Yu, C.-F., & Chen, F.-H. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02673-0 · Cited by 1
“Molecular imaging can address this issue—it is a noninvasive tool that can help quantify changes in tumor biology during treatment in a longitudinal way [14].”
Advances in Imaging of Pancreatic Adenocarcinoma
Dennahy, I. S., & Bonds, M. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.03.003 · Cited by 1
Langerhans Cell Histiocytosis With MAP2K1E102_I103del Mutation Successfully Treated With Trametinib
Lang, M., Chang, L., & Cao, X.-X. (2025) · eJHaem · doi:10.1002/jha2.70067 · Cited by 1
“The residual right axillary uptake may reflect either persistent LCH activity or more likely an inflammatory process (Figure 1b,d,f,h) [9].”
PET-based Quantitative Techniques in Assessing Efficacy of Interventional Radiology Procedures in Oncology
Adnan, A., & Basu, S. K. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.03.005
Frequently Asked Questions on Imaging in Chimeric Antigen Receptor T-Cell Therapy Clinical Trials
Won, S. E., Lee, E. S., Suh, C. H., Kim, S., Park, H. J., Kim, K. W., & Guenette, J. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2024.1126 · Cited by 1
“The Lugano criteria, presented at the 2014 International Workshop on Malignant Lymphoma, revised and redefined the Cheson criteria by incorporating kjronline.org tumor response during treatment by determining whether the tumor has responded, remained stable, or worsened [14].”
Advancements in Prostate Cancer Radiotherapy: The Role of PSMA PET Imaging.
Lester-Coll, N., Pra, A. D., Murthy, V., & Kamran, S. (2025) · Practical Radiation Oncology · doi:10.1016/j.prro.2025.03.008 · Cited by 1
Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer
Ahn, J., Song, Y. S., Kim, B., Yang, S., Jung, K., Lee, J.-C., Kim, J., & Hwang, J.-H. (2025) · Gut and Liver · doi:10.5009/gnl240458 · Cited by 1
“10 ,11-15 Additionally, several studies have explored the relevance of these parameters to pancreatic cancer.”
Prognostic Value of Very Early Interim FDG PET/CT After Single Cycle of Chemotherapy for 10-Year Survival in Diffuse Large B-Cell Lymphoma
Han, E. J., Park, H., Yahng, S.-A., Min, G.-J., Choi, B., Park, G., O, J., & Cho, S. (2025) · Cancers · doi:10.3390/cancers17060926 · Cited by 1
“Metabolic decline in lymphoma lesions occurs immediately and rapidly after the initiation of chemotherapy [9,10].”
Association of loss of visceral adipose tissue after concurrent chemoradiotherapy with poor survival in patients with head and neck squamous cell carcinoma
Lee, S. M., Jo, I. Y., Park, J. H., Kim, M., Choi, H. J., Lee, J. W., & Jang, S. J. (2025) · Nutrition · doi:10.1016/j.nut.2025.112775 · Cited by 1
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer
Vera, P., Giraud, P., Hapdey, S., Gouel, P., Jan, O., Roux, P. L., Langlais, A., Lévêque, E., le Tinier, F., Olivier, A., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268499 · Cited by 1
Axial bone involvement in sarcoidosis has a good prognosis: Longitudinal study of a cohort of 48 patients.
Challal, S., Riviere, E., Lanseur, B., Jeny, F., Nunes, H., Soussan, M., Boissier, M., Semerano, L., & Saidenberg-Kermanac'h, N. (2025) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2025.152654 · Cited by 1
Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer
Wang, J. H., Shi, X., Tran, P. T., & Sutera, P. A. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.01.001 · Cited by 1
Metabolic parameter of baseline 18 F-FDG PET/CT with PINK models improve the prediction of treatment outcome in extranodal NK/T-cell lymphoma treated with P-GEMOX chemotherapy
Huang, C., Li, Y., He, H., Gao, Y., Zhang, X., Bai, B., Ping, L., He, Y.-X., Bai, S.-M., Wang, X.-X., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06243-y · Cited by 1
“Similarly, MTV was found to be the significant independent predictor in 50 cases of NKTCL treated with the MESA-based regimen recently [31].”
High resolution chest computed tomography responses for a cohort of adult with pulmonary Langerhans cell histiocytosis
Chang, L., Wang, L., Liu, Z.-Z., Lang, M., Lin, H., Liu, X.-Y., Duan, M.-H., Zhou, D.-B., & Cao, X.-X. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06167-z · Cited by 1
“Disease response was assessed per PET Response Criteria in Solid Tumors (PERCIST 1.0) [14].”
Influential
Future directions in the evaluation and management of newly diagnosed metastatic cancer.
Lehrer, E., Khunsriraksakul, C., Garrett, S., Trifiletti, D., Sheehan, J., Guckenberger, M., Louie, A. V., Siva, S., Ost, P., Goodman, K., et al. (2025) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2025.104631 · Cited by 1
Radionuclide treatments of cancer: molecular mechanisms, biological responses, histopathological changes, and role of PET imaging
Sarikaya, I. (2024) · Nuclear medicine communications · doi:10.1097/mnm.0000000000001941 · Cited by 1
“Various PET criteria are available to assess response to RNTs [74,75].”
Clinical study of different interventional treatments for primary hepatocellular carcinoma based on propensity-score matching
Cheng, X.-B., Yang, L., Lu, M., Peng, Y.-B., Wang, L., Zhu, S.-M., Hu, Z.-M., Wang, Z.-L., & Yang, Q. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i11.3463 · Cited by 1
Shifting the Landscape of Spine and Non-Spine Bone Metastases
Udovicich, C., Lo, S., Guckenberger, M., & Sahgal, A. (2024) · Cancer Journal · doi:10.1097/ppo.0000000000000755 · Cited by 1
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18F-FDG PET/CT scans
Yang, L., Zeng, L., Wang, S., Wei, L.-Q., Yang, J., Li, M., & Wang, L. (2024) · Leukemia and Lymphoma · doi:10.1080/10428194.2024.2416026 · Cited by 1
“Given the lower dependence on body habitus variations among different populations of lean body mass, it was chosen for normalization instead of total body mass [15].”
The prognostic value of [18F]FDG PET/CT texture analysis prior to transplantation for unresectable colorectal liver metastases
Stern, N. M., Mikalsen, L. T. G., Dueland, S., Schulz, A., Line, P., Stokke, C., & Grut, H. (2024) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12908 · Cited by 1
Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT
Bupathi, M., Garmezy, B., Lattanzi, M., Kieler, M., Ibrahim, N., Perk, T., Weisman, A., & Perlman, S. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206168 · Cited by 1
“Some institutions have implemented standardized response criteria such as RECIST and PERCIST [6,7].”
Method
Effects of PET image reconstruction parameters and tumor-to-background uptake ratio on quantification of PET images from PET/MRI and PET/CT systems
Hussain, A. A., Forssell-Aronsson, E., Rosholm, T., & Mehrara, E. (2024) · Brazilian Journal of Radiation Sciences · doi:10.15392/2319-0612.2024.2487 · Cited by 1
“Standardized uptake value (SUV) is a semi-quantitative measure for tumor uptake and is used as a parameter to assess tumor response to treatment [1].”
Automatic detection and segmentation of lesions in 18F-FDG PET/CT imaging of patients with Hodgkin lymphoma using 3D dense U-Net
Izadi, M., Alemohammad, N., Geramifar, P., Salimi, A., Paymani, Z., Eisazadeh, R., Samimi, R., Nikkholgh, B., & Sabouri, Z. (2024) · Nuclear medicine communications · doi:10.1097/mnm.0000000000001892 · Cited by 1
“To generate ground truth data for this study, two experts performed image segmentation using the PERCIST method [19] and the seeded region growing algorithm [20].”
Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study
Guler, O., Hurmuz, P., Atalar, B., Guney, Y., Sağlam, E., Akyurek, S., Bolukbasi, Y., Gural, Z., Tuğrul, F., Korcum, A., et al. (2024) · Strahlentherapie und Onkologie (Print) · doi:10.1007/s00066-024-02291-x · Cited by 1
“For metabolic response evaluation, Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST), version 1.0, was used [22].”
Influential
Prognostic value of 18F-FDG PET/CT in postoperative recurrence of retroperitoneal liposarcoma: a single-center retrospective study
Lang, J.-T., Liu, W.-S., Liu, G.-B., Liu, S.-W., & Zhang, Y.-Q. (2024) · Nuclear medicine communications · doi:10.1097/mnm.0000000000001886 · Cited by 1
“In the present study, SUV peak was also a prognostic indicator of patients with LPS, making it more suitable for clinical practice, especially for treat-ment response assessment, such as adjuvant therapy in patients with LPS [20].”
Radiographic Response Assessments and Standardized Imaging Interpretation Criteria in Head and Neck Cancer on FDG PET/CT: A Narrative Review
Schroeder, J. A., Oldan, J. D., Jewells, V. L., & Bunch, P. M. (2024) · Cancers · doi:10.3390/cancers16162900 · Cited by 2
“…concise language with four specific categories (i.e., complete response, partial response, stable disease, progressive disease) that could be assigned for the overall clinical assessment; however, a numerical scale—a feature of many other SICs that facilitates maximum conciseness—is not used [17].”
BackgroundResultInfluential
Carbon Ion Beam Radiation Therapy as Part of a Trimodal Therapy for Non-small Cell Superior Sulcus Tumors: The INKA Study
Weykamp, F., Schaub, L., Eichhorn, M. E., Winter, H., Schirmacher, P., Thomas, M., Haberkorn, U., Ellerbrock, M., Adeberg, S., Debus, J., et al. (2024) · Advances in Radiation Oncology · doi:10.1016/j.adro.2024.101573 · Cited by 1
“…Tumors 1.0) based on CT scan, the metabolic response (Positron Emission Tomography Response Criteria in Solid Tumors 1.0) described by Wahl et al 8 based on FDG-PET, the histopathologic tumor regression according to the Junker classi ﬁ cation (grade 1, no or only slight tumor regression; grade…”
MethodInfluential
Predictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy – A Multicenter Study in Japan
Shimizu, K., Nakata, M., Saisho, S., Inubushi, M., Okumura, N., Murakawa, T., Yamashita, M., Nakamura, H., Sano, Y., Kataoka, K., et al. (2024) · Cancer Management and Research · doi:10.2147/cmar.s464265 · Cited by 1
“10 The usefulness of PERCIST in evaluating treatment effects has been reported for several cancers.”
Background
Towards AI Lesion Tracking in PET/CT Imaging: A Siamese-based CNN Pipeline applied on PSMA PET/CT Scans
Hein, S. P., Schultheiss, M., Gafita, A., Zaum, R., Yagubbayli, F., Tauber, R., Rauscher, I., Eiber, M., Pfeiffer, F., & Weber, W. A. (2024) · arXiv.org · doi:10.48550/arxiv.2406.09327 · Cited by 1
“[15] However, the operator dependent selection of index lesions may bias the results due to possible significant inter-metastatic heterogeneity of response to therapy.”
Background
Validation of the 2018 FIGO staging system for stage IIIC cervical cancer by determining the metabolic and radiomic heterogeneity of primary tumors based on 18F-FDG PET/CT
Zhang, Y., Hu, Y.-X., Zhao, S., & Xu, S.-S. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04226-7 · Cited by 1
“SUL is the SUV normalized by lean body mass, while SUS is the SUV normalized by body surface area [31].”
Fluorine-18 FDG PET/CT and New NIMS Grading System for Chemotherapy Response in Breast Cancer
Vakati, G. R., Ratnagiri, R., & Srivastava, M. (2024) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_117_23 · Cited by 1
“This criterion is based on the percentage change in SUL and does not include TLG. [10] In this study, we aimed to assess the ability of PET‑CT to predict response to chemotherapy in patients with breast cancer, to study the correlation between PET‑CT parameters and pathologic response of breast…”
Method
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
Yıldız, A., Bilici, A., Acıkgoz, O., Hamdard, J., Basım, P., Çakır, T., Çakır, A., Olmez, O. F., Gezen, C., & Yildiz, O. (2024) · Journal of chemotherapy · doi:10.1080/1120009x.2024.2314830 · Cited by 1
“The metabolic and anatomical response to treatment was assessed using 18 F-FDG PET/CT images according to the PET Response Criteria in Solid Tumors [15].”
Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma
Tang, P., Cui, F.-T., Jiang, C., Zhou, Y., Su, M.-G., & Tian, R. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005068 · Cited by 1
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials
Muzi, M., Peterson, L., Specht, J., Hippe, D., Novakova-Jiresova, A., Lee, J. H., Kurland, B., Mankoff, D., Obuchowski, N. A., Linden, H., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3818932/v1 · Cited by 1
A Perspective: The Integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for Phase II Immunotherapy Clinical Trials
Kuş, T., & Çiçin, İ. (2024) · Immunotherapy · doi:10.2217/imt-2023-0184 · Cited by 1
Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the detection of recurrence and peritoneal metastasis from ovarian cancer in correlation with cancer antigen-125 tumor marker levels
Elsayed, G. A., Abdullah, R., Elia, R. Z., & Ahmed, K. S. (2024) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-023-01153-3 · Cited by 1
“Guided by the PERCIST criteria published by the Journal of Nuclear Medicine 2009 [10], the target lesion that was measured for intensity during pre-and post-treatment scans did not necessarily remain the same.”
Method
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors
Martella, S., Aiello, M., Bertaglia, V., Cau, R., Denaro, N., Cadoni, A., Novello, S., Scartozzi, M., Novello, G., Parra, H. S., et al. (2023) · Targeted oncology · doi:10.1007/s11523-023-01017-w · Cited by 1
“Finally, the metabolic response to treatment can be assessed using 18 FDG PET/CT with the European Organization for Research and Treatment of Cancer (EORTC) criteria [38] or the PET Response Criteria in Solid Tumors (PERCIST) criteria [39].”
Influence of metabolic tumor burden on reference tissues’ standardized uptake values in ^18F-FDG PET/CT sequential imaging
Badawy, A., Maamoun, M., Kandeel, A., & Anwar, H. (2023) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-023-01140-8 · Cited by 1
“…i.e., superscan phenomenon [6–8], especially those that have been proposed for semiquantitative analysis (such as the liver or blood pool) for evaluating the tumors’ metabolic response to therapy such as PET Response Criteria in Solid Tumors (PERCIST) [9] or the Deauville five-point scale [10].”
Background

Authors: Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A.
Affiliations: Johns Hopkins University (US)
Corresponding author: Wahl, Richard L.
ORCID: Wahl, Richard L.
Jacene, Heather
Kasamon, Yvette
Lodge, Martin A.
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2009-04-29
Volume: 50
Issue: Suppl 1
Pages: 122S-150S
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.108.057307
PMC: PMC2755245
OpenAlex: W2155263737
Cited by: 3,777
References: 157
Citations by year: 2026: 180 · 2025: 200 · 2024: 197 · 2023: 230 · 2022: 248 · 2021: 309 · 2020: 271 · 2019: 259 · 2018: 225 · 2017: 274 · 2016: 246 · 2015: 245 · 2014: 221 · 2013: 230 · 2012: 192
FWCI: 21.01
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (CA006973, P30CA006973)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: RECIST, PERCIST, 18F-FDG PET, tumor response assessment, standardized uptake value, WHO criteria, RECIST 1.1, region of interest, treatment response assessment, solid tumors, lymphoma, sarcoma, hepatocellular carcinoma, mesothelioma, gastrointestinal stromal tumor, test-retest variability
MeSH terms: Forecasting, Humans, Neoplasms, Prognosis, World Health Organization, Treatment Outcome, Outcome Assessment, Health Care, Practice Guidelines as Topic, Radiopharmaceuticals, Fluorodeoxyglucose F18, Internationality, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks